Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022


Naperville, IL -- (SBWIRE) -- 04/30/2014 -- Reportstack, provider of premium market research reports announces the addition of Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022 market report to its offering
Remicade (Ulcerative Colitis) - Forecast and Market Analysis to 2022


During the forecast period from 2012-2022, the growth of the UC market will be driven largely by the entry of Johnson & Johnsons (J&Js) Simponi and Takedas Entyvio, which will lead to an increase in the overall number of patients being treated with biologics in the US, 5EU, Japan, and Canada. Another key event affecting the UC market is the anticipated launch of biosimilars, given that the patent expiry of the UC blockbusters, Remicade and Humira are set to expire in the US in 2018 and 2016, respectively.

Remicade (infliximab) is a TNF-a inhibitor that was originally developed by Centocor Ortho Biotech, which is now Janssen Biotech, a subsidiary of J&J. _x000D_Upon the onset of intestinal inflammation in IBD, a rather aggravated immune response is initiated that is skewed towards a specific T-cell phenotype. This T-cell group (Th1) is attracted to the site of inflammation, where additional white blood cells are recruited. Th1 cells produce large amounts of an inflammatory protein called INF-?, which, in turn, induces the production of the pro-inflammatory cytokine TNF-a in both local and recruited macrophages, as well as in the intestinal epithelial cells


- Overview of Ulcerative Colitis, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape._x000D_
- Detailed information on Remicade including product description, safety and efficacy profiles as well as a SWOT analysis._x000D_
- Sales forecast for Remicade for the top ten countries from 2012 to 2022._x000D_
- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return_x000D_
- Stay ahead of the competition by understanding the changing competitive landscape for Ulcerative Colitis_x000D_
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential_x000D_
- Make more informed business decisions from insightful and in-depth analysis of Remicade performance _x000D_
- Obtain sales forecast for Remicade from 2012-2022 in the top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Canada, China and India)

To view the table of contents for this market research report please visit
Roger Campbell
United States
Ph: 888-789-6604